Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study

Table 1 Baseline patient demographics and burden of disease.

	Interferon beta-1a treatment group
	44 mcg sc tiw (n = 279)	30 mcg im qw (n = 274)	p value*
Age in years, mean (SD)	38.6 (8.8)	37.7 (8.6)	0.188
Sex, n (%)			0.269
Men	64 (22.9)	74 (27.0)
Women	215 (77.1)	200 (73.0)
Race, n (%)			0.935
White	258 (92.5)	250 (91.2)
Black	12 (4.3)	15 (5.5)
Asian	0	1 (0.4)
Hispanic	5 (1.8)	4 (1.5)
Other	4 (1.4)	4 (1.5)
BOD in mm³, median (range)	5438 (85–135276)	6010 (391–103495)	0.541

*Treatment comparisons with respect to sex and race distributions were performed using a Chi-squared test or a Fisher's Exact test, where appropriate. With respect to age and baseline BOD, an analysis of covariance model using ranked data was performed with effects for treatment.
Numbers do not add to 100% due to rounding.
BOD, burden of disease; im, intramuscular; qw, once weekly; sc, subcutaneous; SD, standard deviation; tiw, three times weekly.

ISSN: 1471-2377